Serotonin Syndrome

Aka: Serotonin Syndrome, Serotonergic Medication

advertisement

II. Background: History

  1. Libby Zion was a young patient who died of Serotonin Syndrome in 1984 and set historic precedent
    1. Provider education regarding Serotonin Syndrome
    2. Principal case that limited intern and resident shift hours
    3. http://en.wikipedia.org/wiki/Libby_Zion_law

III. Epidemiology

  1. Complicates 14-16% of SSRI Overdoses
    1. Isbister (2004) J Toxicol Clin Toxicol 42(3): 277-85 [PubMed]

IV. Etiology

  1. Excessive Serotonin levels at the 5HT-2A receptor sites
  2. Associated with combinations of Serotoninergic drugs (e.g. SSRI, TCA, MAOI)
  3. Exacerbated by drugs that increase Serotonin levels (see risk factors below)

V. Risk Factors: General

  1. Medications with serotonergic effects (see below)
    1. Combined use of multiple serotonergic drugs
    2. Inadequate washout period between transitioning to a new serotonergic drug
    3. Higher Incidence with Monoamine Oxidase Inhibitors, St. John's Wort and Linezolid
  2. Cytochrome P450 Drug Interactions or specific patient Phenotypes
    1. Examples: Clarithromycin
    2. Increases susceptibility to Serotonin Syndrome
  3. Medical conditions that decrease the available monoamine oxidase
    1. Hypertension
    2. Atherosclerosis
    3. Hyperlipidemia

VI. Risk Factors: Serotonergic Medications

  1. Psychiatric medications
    1. Selective Serotonin Reuptake Inhibitors - SSRI (e.g. Paroxetine/Paxil or Fluoxetine/Prozac)
    2. Serotonin-Norepinephrine Reuptake Inhibitors - SNRI (e.g. Venlafaxine - Effexor)
    3. MAO Inhibitors (e.g. Phenelzine, Selegiline or Nardil)
      1. High risk for Serotonin Syndrome when combined with other serotinergic agents
    4. Tricyclic Antidepressants (e.g. Amitriptyline, Clomipramine, Imipramine)
    5. Lithium
    6. Buspar
    7. Trazodone
      1. Lower risk of Serotonin Syndrome (non-Serotonin 2A stimulation)
    8. Some Antipsychotic Medications (e.g. Olanzapine or Zyprexa)
  2. Stimulant Medications
    1. Methylphenidate (Ritalin)
    2. Sibutramine (Meridia)
  3. Antiemetics
    1. Metoclopramide (Reglan)
    2. Ondansetron (Zofran)
      1. Lower risk of Serotonin Syndrome (non-Serotonin 2A stimulation)
    3. Droperidol (Inapsine)
  4. Migraine and Seizure Medications
    1. Triptans (e.g. SumatriptanImitrex)
      1. Lower risk of Serotonin Syndrome (non-Serotonin 2A stimulation)
    2. Ergot Alkaloids
    3. Valproic Acid (Depakote, Depakene)
    4. Carbamazepine (Tegretol)
  5. Synthetic Opioid Analgesics
    1. Tramadol (Ultram)
      1. Higher risk for Serotonin Syndrome
    2. Meperidine (Demerol)
    3. Fentanyl (Duragesic)
    4. Methadone
    5. Dextromethorphan
    6. Rare case reports with Buprenorphine (Suboxone), Hydromorphone, Oxycodone or Hydrocodone
  6. Muscle Relaxants
    1. Cyclobenzaprine (Flexeril)
    2. Metaxalone (Skelaxin)
  7. Miscellaneous medications
    1. Chlorpheniramine
    2. Linezolid (Zyvox) - MAO Inhibitor effect
    3. Reserpine
    4. Ritonavir (Norvir)
    5. Locaserin (weight loss agent)
  8. Herbals and supplements
    1. St. John's Wort
    2. Ginkgo Biloba
    3. Ginseng
    4. L-Tryptophan
    5. 5-Hydroxytryptophan (dietary supplement) - Serotonin precursor
    6. Yohimbine
  9. Recreational drugs
    1. Cocaine
    2. 3,4-methylenedioxmethamphetamine (Ecstacy)
    3. Methamphetamine

VII. Signs

  1. Mental Status Changes
    1. Confusion or Disorientation (51%)
    2. Agitation or irritability (34%)
    3. Somnolence, coma or unresponsiveness (29%)
  2. Autonomic changes
    1. Fever or hyperthermia (45%)
      1. Muscle hyperactivity and decreased heat dissipation
    2. Diaphoresis (45%)
    3. Sinus Tachycardia (36%)
    4. Hypertension (35%)
    5. Mydriasis (28%) or unreactive pupils (20%)
    6. Tachypnea (26%)
    7. Nausea (23%) or Vomiting
  3. Neuromuscular changes
    1. Myoclonic Jerks (58%)
    2. Hyperreflexia (52%)
    3. Muscle rigidity (51%)
    4. Restlessness or hyperactivity (48%)
    5. Tremor (43%)
    6. Ataxia or Incoordination (40%)
    7. Clonus (23%)
      1. Spontaneous Clonus with a history of Serotoninergic agent use is pathognomonic for Serotonin Syndrome
      2. Dunkley (2003) QJM 96 (9): 635-642 [PubMed]
  4. Exclude other possible causes
    1. Infectious, metabolic, Substance Abuse or withdrawal
    2. No recent Neuroleptic changes

VIII. Precautions

  1. Subtle Serotonin Syndrome presentations are far more common than severe Serotonin Syndrome (e.g. Delirium, hyperthermia)
  2. Remain alert for more subtle findings (e.g. Agitation, diaphoresis, Tremor)
    1. Focus on times of dose increase and times of new medications (especially in combination)

IX. Diagnosis: Hunter Serotonin Criteria

  1. Major Criteria
    1. Ingestion of serotinergic agent
  2. Other Criteria (at least one present)
    1. Tremor AND Hyperreflexia
    2. Spontaneous Clonus
    3. Ocular Clonus or Inducible Clonus AND one of the following
      1. Hypertonia AND Body Temperature > 100.4 F (38 C) OR
      2. Agitation
      3. Diaphoresis
  3. Efficacy
    1. Test Sensitivity: 84%
    2. Test Specificity: 97%
  4. References
    1. Dunkley (2003) QJM 96(9):635-42 +PMID: 12925718 [PubMed]

X. Differential Diagnosis

  1. Meningitis or Encephalitis
  2. Anticholinergic Syndrome
  3. Malignant Hyperthermia
  4. Seizure Disorder
  5. Neuroleptic Malignant Syndrome
    1. Occurs with Dopamine blocking agents
    2. Classic triad of fever, Muscle rigidity and Altered Mental Status

XI. Management

  1. Discontinue Serotoninergic medications
  2. Provide supportive care
  3. Treat Muscle rigidity, Tremor and hyperthermia
    1. First line
      1. Benzodiazepines decrease Agitation and adrenergic stress
    2. Refractory Hyperthermia (severe, critically ill patients)
      1. Active Cooling of Patient
      2. Endotracheal Intubation
      3. Sedation and Paralytic Agents (non-depolarizing Neuromuscular Blockers, e.g. Rocuronium)
  4. Consider serotonin Antagonists
    1. Cyproheptadine (Periactin)
      1. Initial protocol
        1. Bolus: 12 mg oral bolus dose for 1 dose (may be crushed and placed down NG or OG)
        2. Continued symptoms: 2 mg every 2 hours until symptoms controlled
        3. Expect patient sedation with Cyproheptadine dosing
      2. Maintenance protocol (once stabilized)
        1. Dose: 8 mg every 6 hours or 4 mg every 2-4 hours
        2. Maximum: 0.5 mg/kg/day
  5. Other medications that have been used for Serotonin Syndrome symptom control
    1. Propranolol
  6. Precautions
    1. Avoid Antipsychotics (e.g. Haloperidol) as has serotonergic effects and may exacerbate condition
    2. Avoid antipyretics (ineffective)
      1. Hyperthermia of Serotonin Syndrome is due to increased Muscle activity (not the Hypothalamus)

XII. Course

  1. Many cases likely go undiagnosed and resolve spontaneously when patients stop the medications themselves
  2. Resolution after stopping Serotoninergic medication
    1. Within 24 hours in 70% of cases
    2. Within 96 hours in almost all cases
  3. High acuity care
    1. Intensive Care admission in up to 40% of cases
    2. Mechanical Ventilation in up to 25% of cases
  4. Rarely fatal: 11 deaths in literature

XIII. References

  1. Herbert and Jhun in Herbert (2015) EM:Rap 15(4):14
  2. Nordt and Swadron in Majoewsky (2012) EM:Rap 12(2): 3
  3. Otter and Tomaszewski (2018) Crit Dec Emerg Med 32(11): 28
  4. (2022) Presc Lett 29(9): 51-2
  5. Ables (2010) Am Fam Physician 81(9): 1139-42 [PubMed]
  6. Bodner (1995) Neurology 45:219-23 [PubMed]
  7. Brown (1996) Ann Pharmacother 30:529-33 [PubMed]
  8. Corkeron (1995) Med J Aust 163:481-2 [PubMed]
  9. Erner (2003) Pain Med 4(1): 63-74 [PubMed]
  10. Iqbal (2012) Ann Clin Psychiatry 24(4): 310-8 [PubMed]
  11. Kovich (2015) Am Fam Physician 92(2): 94-100 [PubMed]
  12. Mills (1995) Am Fam Physician 52(5):1475-82 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Serotonin Syndrome." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Ontology: Malignant Carcinoid Syndrome (C0024586)

Definition (NCI) A syndrome characterized by signs and symptoms caused by advanced carcinoid tumors. They include skin flushing, diarrhea, wheezing, and tachycardia.
Definition (NCI_NCI-GLOSS) A combination of symptoms caused by the release of serotonin and other substances from carcinoid tumors of the gastrointestinal tract. Symptoms may include flushing of the face, flat angiomas (small collections of dilated blood vessels) of the skin, diarrhea, bronchial spasms, rapid pulse, and sudden drops in blood pressure.
Definition (MSH) A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)
Concepts Disease or Syndrome (T047)
MSH D008303
ICD9 259.2
ICD10 E34.0
SnomedCT 109950000, 190580007, 154717002, 35868009
English Carcinoid Syndrome, Malignant, Carcinoid Syndromes, Malignant, Malignant Carcinoid Syndrome, Malignant Carcinoid Syndromes, Syndromes, Malignant Carcinoid, CARCINOID SYNDROME, Syndrome, Malignant Carcinoid, carcinoid syndrome (diagnosis), carcinoid syndrome, Malignant Carcinoid Syndrome [Disease/Finding], serotonin syndrome, malignant carcinoid syndrome, carcinoids syndrome, syndrome serotonin, Hormonal tumor (disorder), Malignant carcinoid syndrome, Serotonin syndrome, Carcinoid syndrome, Hormone secretion by carcinoid tumor, Excessive serotonin secretion, Hormone secretion by carcinoid tumour, Carcinoid syndrome (disorder), Hormonal tumor, Hormonal tumour, carcinoid; hormone secretion, tumor, carcinoid; syndrome, hormone secretion; carcinoid tumor, secretion; carcinoid tumor, hormone, syndrome; carcinoid, Carcinoid Syndrome, Hormone secretion by carcinoid tumors
Italian Sindrome carcinoide, Sindrome da carcinoide maligno
Japanese カルチノイド症候群, ｶﾙﾁﾉｲﾄﾞｼｮｳｺｳｸﾞﾝ
Swedish Malignt karcinoidsyndrom
Czech maligní karcinoidní syndrom, Karcinoidní syndrom
Finnish Pahanlaatuinen karsinoidioireyhtymä
Russian KARTSINOID ZLOKACHESTVENNYI, КАРЦИНОИД ЗЛОКАЧЕСТВЕННЫЙ
Korean 카르시노이드 증후군
Polish Zespół rakowiaka
Hungarian Carcinoid syndroma
Norwegian Malignt karsinoid-syndrom
Portuguese Síndrome do Carcinoide Maligno, Síndrome carcinóide
Spanish tumor hormonal, tumor hormonal (trastorno), secreción de hormonas por el tumor carcinoide, síndrome carcinoide (trastorno), síndrome carcinoide, síndrome de serotonina, síndrome serotoninérgico, Síndrome carcinoide, Síndrome Carcinoide Maligno
Dutch carcinoïd; hormoonsecretie, tumor, carcinoïd; syndroom, hormoonsecretie; carcinoïdtumor, secretie; carcinoïdtumor, hormoon, syndroom; carcinoïd, Carcinoïdsyndroom, carcinoïdsyndroom, Carcinoïdsyndroom, maligne, Maligne carcinoïdsyndroom, Syndroom, maligne carcinoïd-
German Karzinoid-Syndrom, Malignes Karzinoidsyndrom, Cassidy-Scholte-Syndrom, Karzinoidsyndrom, Biörck-Thorson-Syndrom
French Carcinoïdose, Syndrome carcinoïde, Syndrome carcinoïde malin, Syndrome de Björk
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

advertisement

2025 Family Practice Notebook, LLC. Terms | Privacy | About | Site Map | Newsletter | Blog

Footer Site Logo